Blood Pressure Targets Just Changed

This protocol is the centrepiece of the entire video. The historical data from insurance actuarial tables in 1925, the Framingham Heart Study, and early VA trials showed continuous risk reduction down to at least 115/75 mmHg. The SPRINT trial proved that targeting <120 mmHg instead of the then-standard <140 mmHg cut major cardiovascular events by 27% and all-cause death by 25%, with the trial halted early for overwhelming benefit. A large Chinese replication extended the benefit to broader populations, including diabetics, with a 21% reduction in all-cause death. The newest evidence adds dementia risk reduction. Stanfield stresses that this is not a blanket mandate; clinical judgment is needed for older adults where the risk of overly low blood pressure (e.g., orthostatic hypotension causing falls) may outweigh the benefit. In his practice, he tailors the target, sometimes keeping the systolic a bit above 120 if a patient is frail. However, for the vast majority, the goal is aggressive: below 120 mmHg.

The 2024 guidelines break new ground by explicitly endorsing salt substitutes. Brad Stanfield explains that the typical salt substitute is ordinary salt mixed with potassium salt, so it reduces sodium intake while boosting potassium — both of which are known to lower blood pressure. He ties this directly to his own supplement formulation: he includes a small amount of potassium in microvitamin because of the blood pressure benefits of potassium. The protocol is straightforward: switch your salt shaker to a potassium-enriched product. This is a low-cost, high-impact intervention that can be applied at the population level without medical oversight, and the guidelines now say it's appropriate even if your blood pressure is currently normal, aiming at primary prevention.

The new guidelines, published in August (presumably 2024), do not lower the numeric thresholds for hypertension but completely change the clinical approach. For patients with hypertension and elevated cardiovascular risk, they now explicitly say to shoot for less than 130 mmHg systolic, with a preference for 120 or below. This is backed by the SPRINT trial (27% lower cardiovascular events) and its Chinese replication (12% lower cardiovascular events, 21% lower all-cause death). Equally important is a new emphasis on starting treatment earlier: patients at lower risk categories get lifestyle changes first, but if blood pressure targets aren't reached within 3 to 6 months, medications are now encouraged — this shortens the window of inaction. The guidelines also break new ground by recommending salt substitutes, typically a mix of sodium chloride and potassium chloride, to lower sodium and boost potassium intake simultaneously, a strategy previously not universally endorsed. Stanfield supports this fully, noting that potassium's blood-pressure-lowering effects are why he includes a small amount of potassium in his own microvitamin supplement.

The SPRINT dementia study is the latest piece of a mounting puzzle. The parent SPRINT trial was stopped early after just 3.3 years because the benefit was so clear. This follow-up analysis examined incident dementia over the entire follow-up period and found a 14% relative risk reduction. Stanfield uses this to counter the narrative that lowering blood pressure too much might starve the brain of blood flow; instead, the evidence suggests high blood pressure damages small vessels in the brain, and lowering it prevents cognitive decline. Combined with the Chinese replication study (over 11,000 people, including diabetics and stroke survivors, with a 21% reduction in all-cause death), the case for aggressive targets now covers cardiovascular, mortality, and cognitive outcomes. Stanfield notes that the dementia risk reduction is particularly persuasive for him in clinic when tailoring advice to individual patients, especially since dementia is a top fear among older adults.

After detailing the historical progression from 1948 textbooks calling 180/110 'high' to the 2017 guidelines setting 120 as normal, Stanfield bluntly concludes that the data unequivocally supports lower targets. He points to the SPRINT trial's 25% mortality reduction and the Chinese trial's 21% all-cause death reduction as game-changing results that no influencer can ethically dismiss. His central message is that influencers who encourage people to ignore their high blood pressure are actively preventing them from achieving life-saving interventions. He sees this as a personal mission in his clinic and online content — to counteract the false narrative and get people to treat their blood pressure before it causes a heart attack, stroke, or dementia.